according to businessinsider
Reports: Pfizer close to buying Medivation for $14 billion
Reports: Pfizer close to buying Medivation for $14 billion
Pfizer is reportedly close to scooping up cancer drugmaker Medivation for $14 billion.The Financial Times and Bloomberg are reporting that the deal could close as soon as Monday, citing people close to the deal.A $14 billion deal would value Medivation at more than $80 a share, a notable premium to the $52.50-a-share offer the pharma giant Sanofi had made earlier this year.Medivation shares ended trading at $67.16 on Friday.
coupled with reuters
Pfizer nears deal to acquire Medivation for close to $14 billion
Pfizer nears deal to acquire Medivation for close to $14 billion
The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S., August 1, 2016.REUTERS/Andrew KellyThe Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S., August 1, 2016.REUTERS/Andrew KellyPfizer Inc (PFE.N) is in advanced talks to acquire U.S. cancer drug company Medivation Inc (MDVN.O) for close to $14 billion, as it seeks to boost its oncology portfolio, people familiar with the matter said on Sunday.Pfizer has agreed to pay a little more than $80 per share for Medivation, one of the people said, a substantial premium to the $52.50 offer for Medivation that France's Sanofi SA (SASY.PA) made in April, which eventually resulted in the company putting itself up for sale.
by the same token on yahoo
Pfizer nears deal to acquire Medivation for close to $14 billion
Pfizer nears deal to acquire Medivation for close to $14 billion
By Greg Roumeliotis(Reuters) - Pfizer Inc is in advanced talks to acquire U.S. cancer drug company Medivation Inc for close to $14 billion, as it seeks to boost its oncology portfolio, people familiar with the matter said on Sunday.Pfizer has agreed to pay a little more than $80 per share for Medivation, one of the people said, a substantial premium to the $52.50 offer for Medivation that France's Sanofi SA made in April, which eventually resulted in the company putting itself up for sale.Medivation shares ended trading in New York on Friday at $67.16.Reuters reported earlier this week that Pfizer, Sanofi, Merck & Co Inc , Celgene Corp and Gilead Sciences Inc had submitted expressions of interest to acquire Medivation.
No comments:
Post a Comment